The increase in vaccine procurement is good news in terms of daily vaccination numbers, but govt's stated target of 1 crore daily vaccinations still some time away.
Talks are still on with Moderna, Sputnik yet to be procured for the national Covid vaccination programme, which means Covishield and Covaxin will remain the mainstay.
Pune-based vaccine manufacturer SII has already received cell and vector samples for the production of Sputnik V from Russia's Gamaleya Center, the developer of the vaccine.
Russia's RDIF has also reached agreements with other pharmaceutical companies in India including Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma & Virchow Biotech.
Dr Reddy's, through which Russia's Sputnik V is available in India, said the timeline was pushed a little further due to import dependency, quality checks.
Dr Reddy's Laboratories is in a pact with Russian Direct Investment Fund to sell the first 250 million vials of Sputnik V in India. It has already received nearly 3 million doses.
The permission has been granted for examination, test and analysis of the Sputnik vaccine at SII's licensed Hadapsar facility under certain conditions, official sources said.
Like China, India remains a big domestic market, which will continue to attract investment, but the US tariffs will make India unattractive for future investments.
New bill aims to fix key issues with IBC 2016, including delays & patchy implementation, and protect creditors, with window for genuine promoters to retain control of their companies.
India’s 1st tri-service seminar, on the lines of Shangri-La Dialogue, kicks off in Mhow, with top military officers & defence attaches from several countries in attendance.
Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.
COMMENTS